E-viri
Recenzirano
Odprti dostop
-
Mariathasan, Sanjeev; Turley, Shannon J; Nickles, Dorothee; Castiglioni, Alessandra; Yuen, Kobe; Wang, Yulei; Kadel, III, Edward E; Koeppen, Hartmut; Astarita, Jillian L; Cubas, Rafael; Jhunjhunwala, Suchit; Banchereau, Romain; Yang, Yagai; Guan, Yinghui; Chalouni, Cecile; Ziai, James; Şenbabaoğlu, Yasin; Santoro, Stephen; Sheinson, Daniel; Hung, Jeffrey; Giltnane, Jennifer M; Pierce, Andrew A; Mesh, Kathryn; Lianoglou, Steve; Riegler, Johannes; Carano, Richard A D; Eriksson, Pontus; Höglund, Mattias; Somarriba, Loan; Halligan, Daniel L; van der Heijden, Michiel S; Loriot, Yohann; Rosenberg, Jonathan E; Fong, Lawrence; Mellman, Ira; Chen, Daniel S; Green, Marjorie; Derleth, Christina; Fine, Gregg D; Hegde, Priti S; Bourgon, Richard; Powles, Thomas
Nature (London), 02/2018, Letnik: 554, Številka: 7693Journal Article
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response to treatment was associated with CD8 T-effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden. Lack of response was associated with a signature of transforming growth factor β (TGFβ) signalling in fibroblasts. This occurred particularly in patients with tumours, which showed exclusion of CD8 T cells from the tumour parenchyma that were instead found in the fibroblast- and collagen-rich peritumoural stroma; a common phenotype among patients with metastatic urothelial cancer. Using a mouse model that recapitulates this immune-excluded phenotype, we found that therapeutic co-administration of TGFβ-blocking and anti-PD-L1 antibodies reduced TGFβ signalling in stromal cells, facilitated T-cell penetration into the centre of tumours, and provoked vigorous anti-tumour immunity and tumour regression. Integration of these three independent biological features provides the best basis for understanding patient outcome in this setting and suggests that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.